Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: Still a place in prognostication? Data from the GISSI-HF trial

European Journal of Heart Failure

Volumn 14, Issue 12, 2012, Pages 1410-1419

  La Rovere, Maria Teresa ^a   Pinna, Gian Domenico ^a   Maestri, Roberto ^a   Barlera, Simona ^b   Bernardinangeli, Marino ^c   Veniani, Marco ^d   Nicolosi, Gian Luigi ^e   Marchioli, Roberto ^f   Tavazzi, Luigi ^g  

^a IRCCS   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c USL 4   (Italy)

^d Ospedale Civile   (Italy)

^e Cardiology Unit   (Italy)

^f Consorzio Mario Negri Sud ^*  (Italy)

^g MARIA CECILIA HOSPITAL   (Italy)

Author keywords

Autonomic; Heart Failure; Heart rate turbulence; Heart rate variability; nervous system; Prognosis

Indexed keywords

CREATININE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECELERATION; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE TURBULENCE; HEART RATE VARIABILITY; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SINUS RHYTHM; SUDDEN DEATH;

AGED; ARRHYTHMIAS, CARDIAC; AUTONOMIC NERVOUS SYSTEM; DEFIBRILLATORS, IMPLANTABLE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY, AMBULATORY; FATTY ACIDS, OMEGA-3; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS;

EID: 84870454307     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs126     Document Type: Article

References (29)

1. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, van Veldhuisen DJ; Committee for Practice Guidelines of the European Society of Cardiology. 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 2010;12:1143-1153.
2. Goldberger JJ, Buxton AE, Cain M, Costantini O, Exner DV, Knight BP, Lloyd-Jones D, Kadish AH, Lee B, Moss A, Myerburg R, Olgin J, Passman R, Rosenbaum D, Stevenson W, Zareba W, Zipes DP. Risk stratification for sudden cardiac death. Identifying the roadblocks. Circulation 2011;123:2423-2430.
3. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, Maron BJ, Page RL, Passman RS, Siscovick D, Stevenson WG, Zipes DP. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death. Circulation 2008;118:1497-1518.
4. Buxton AE. Risk stratification for sudden death in patients with coronary artery disease. Hearth Rhythm 2009;6:836-847.
5. Bauer A, Barthel P, Schneider R, Ulm K, Müller A, Joeinig A, Stich R, Kiviniemi A, Hnatkova K, Huikuri H, Schömig A, Malik M, Schmidt G. Improved stratification of autonomic regulation for risk prediction in post-infarction patients with preserved left ventricular function (ISAR-Risk). Eur Heart J 2009;30:576-583.
6. Galinier M, Pathak A, Fourcade J, Androdias C, Curnier D, Varnous S, Boveda S, Massabuau P, Fauvel M, Senard JM, Bounhoure JP. Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur Heart J 2000;21:475-482.
7. La Rovere MT, Pinna GD, Maestri R, Mortara A, Capomolla S, Febo O, Ferrari R, Franchini M, Gnemmi M, Opasich C, Riccardi PG, Traversi E, Cobelli F. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003;107:565-570.
8. GISSI-HF Investigators. Effects of n-3 polyunsatured fatty acids in patients with chronic heart failure (GISSI-HF trial): a randomised, double-blind, placebo controlled trial. Lancet 2008;372:1223-1230.
9. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards and measurement, physiological interpretation, and clinical use. Eur Heart J 1996;17: 354-381.
10. Bauer A, Kantelhardt JW, Barthel P, Schneider R, Mäkikallio T, Ulm K, Hnatkova K, Schömig A, Huikuri H, Bunde A, Malik M, Schmidt G. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet 2006;367:1674-1681.
11. Bauer A, Malik M, Schmidt G, Barthel P, Bonnemeier H, Cygankiewicz I, Guzik P, Lombardi F, Müller A, Oto A, Schneider R, Watanabe M, Wichterle D, Zareba W. Heart rate turbulence: standard of measurements, physiological interpretation, and clinical use. J Am Coll Cardiol 2008;52:1353-1365.
12. La Rovere MT, Maestri R, Pinna GD, Sleight P, Febo O. Clinical and haemodynam-ic correlates of heart rate turbulence as a non-invasive index of baroreflex sensitivity in chronic heart failure. Clin Sci (Lond) 2011;121:279-284.
13. Maestri R, Pinna GD, Accardo A, Allegrini P, Balocchi R, D'Addio G, Ferrario M, Menicucci D, Porta A, Sassi R, Signorini MG, La Rovere MT, Cerutti S. Non linear indices of heart rate variability in heart failure patients: redundancy and comparative clinical value. J Cardiovasc Electrophysiol 2007;18:425-433.
14. Bigger JT Jr, Steinman RC, Rolnitzky LM, Fleiss JL, Albrecht P, Cohen RJ. Power law behaviour of RR-interval variability in healthy middle-aged persons, patients with recent acute myocardial infarction, and patients with heart transplants. Circulation 1996;93:2142-2151.
15. Peng CK, Havlin S, Stanley HE, Golberger AL. Quantification of scaling exponents and crossover phenomena in nonstationary heartbeat time series. Chaos 1995;5: 82-87.
16. Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict outcome in patients with heart failure receiving beta-blockers. J Heart Lung Transplant 2004;23:1414-1422.
17. Harrell FE. Regression Modeling Strategies, With Applications to Linear Models, Logistic Regression and Survival Analysis. New York: Springer-Verlag; 2001.
18. Chambless L, Cummiskey C, Cui G. Several methods to assess improvement in risk prediction model: extension to survival analysis. Stat Med 2011;30:22-38.
19. Mäkikallio T, Barthel P, Schneider R, Bauer A, Tapanainen JM, Tulppo MP, Schmidt G, Huikuri HV. Prediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern treatment era. Eur Heart J 2005;26:762-769.
20. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM. Renal impairment and outcomes in heart failure. Systematic review and meta-analysis. J Am Coll Cardiol 2006;47:1987-1996.
21. Kreuz J, Balta O, Linhart M, Fimmers R, Lickfett L, Mellert F, Nickenig G, Schwab JO. An impaired renal function and advanced heart failure represent independent predictors of the incidence of malignant ventricular arrhythmias in patients with an implantable cardioverter/defibrillator for primary prevention. Europace 2010;12:1439-1445.
22. McAlister FA, Wiebe N, Ezekowitz A, Leung AA, Armstrong PW. Meta-analysis: b-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784-794.
23. Schaer BA, Osswald S, Di Valentino M, Soliman OI, Sticherling C, ten Cate FJ, Jordaens L, Theuns DA. Close connection between improvement in left ventricular function by cardiac resynchronization therapy and the incidence of arrhythmias in cardiac resynchronization therapy-defibrillator patients. Eur J Heart Fail 2010;12:1325-1332.
24. Mrowka R, Persson PB, Theres H, Patzak A. Blunted arterial baroreflex causes 'pathological' heart rate turbulence. Am J Physiol Regul Integr Comp Physiol 2000; 279:1171-1175.
25. La Rovere MT, Pinna GD, Hohnloser SH, Marcus FI, Mortara A, Nohara R, Bigger JT Jr, Schwartz PJ, for the ATRAMI Investigators. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias. Implications for clinical trials. Circulation 2001;103: 2072-2077.
26. Sleight P, La Rovere MT, Mortara A, Pinna G, Maestri R, Leuzzi S, Bianchini B, Tavazzi L, Bernardi L. Physiology and pathophysiology of heart rate and blood pressure variability in humans: is power spectral analysis largely an index of bar-oreflex gain? Clin Sci (Lond) 1995;88:103-109.
27. van de Vooren H, Gademan MG, Swenne CA, TenVoorde BJ, Schalij MJ, van der Wall EE. Baroreflex sensitivity, blood pressure buffering, and resonance: what are the links? Computer simulation of healthy subjects and heart failure patients. J Appl Physiol 2007;102:1348-1356.
28. Guzzetti S, La Rovere MT, Pinna GD, Maestri R, Borroni E, Porta A, Mortara A, Malliani A. Different spectral components of 24 h heart rate variability are related to different modes of death in chronic heart failure. Eur Heart J 2005;26:357-362.
29. Huikuri HV, Mäkikallio TH, Peng CK, Goldberger AL, Hintze U, Møller M. Fractal correlation properties of R-R interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction. Circulation 2000;101:47-53.